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Abstract
The potential role of gender in the occurrence of HIV-related neurocognitive impairment
(NCI) and associations with markers of HIV-related immune activity has not been previously
examined. In this study 149 antiretroviral-naïve seropositive subjects in Nigeria (SP, 92
women and 57 men) and 58 seronegative (SN, 38 women and 20 men) were administered
neuropsychological testing that assessed 7 ability domains. From the neuropsychological
test scores was calculated a global deficit score (GDS), a measure of overall NCI. Percent-
ages of circulating monocytes and plasma HIV RNA, soluble CD163 and soluble CD14 levels
were also assessed. HIV SP women were found to be younger, more educated and had
higher CD4+ T cell counts and borderline higher viral load measures than SPmen. On the
neuropsychological testing, SP women were more impaired in speed of information process-
ing and verbal fluency and had a higher mean GDS than SN women. Compared to SPmen,
SP women were also more impaired in speed of information processing and verbal fluency
as well as on tests of learning and memory. Numbers of circulating monocytes and plasma
sCD14 and sCD163 levels were significantly higher for all SP versus all SN individuals and
were also higher for SP women and for SPmen versus their SN counterparts. Among SP
women, soluble CD14 levels were slightly higher than for SPmen, and SP women had higher
viral load measurements and were more likely to have detectable virus than SPmen. Higher
sCD14 levels among SP women correlated with more severe global impairment, and higher
viral load measurements correlated with higher monocyte numbers and sCD14 and sCD14
levels, associations that were not observed for SPmen. These studies suggest that the risk
of developing NCI differ for HIV infected women and men in Nigeria and, for women, may be
linked to effects from higher plasma levels of HIV driving activation of circulating monocytes.
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Introduction
Neurocognitive impairment is a common consequence of HIV-1 infection and has been
increasing as infected individuals survive longer with treatment with antiretroviral therapy
[1,2]. Clinically, the determination of NCI in HIV-infected individuals is made based on per-
formance on detailed neuropsychological testing combined with evidence of impairment in
functioning in activities in everyday living. In previous studies in Nigeria, evidence of NCI
among HIV infected individuals has been documented using both screening tests and detailed
neuropsychological test batteries [3–6]. These studies have demonstrated the presence of pat-
terns of impairment that are similar to what has been described in other countries in Africa as
well as in more developed areas of the world. This is important because it suggests that infor-
mation which is obtained from such assessments can be applied to determine whether factors
that have been previously linked with an increased risk for developing NCI may also play a role
in the development of the disorder among HIV-infected individuals in Nigeria.
Among the demographic factors that have been studied for possible associations with HIV
disease progression in the development of NCI is gender. In a small study performed in Zambia
in which HIV seronegative (SN) and seropositive (SP) individuals were administered a detailed
neuropsychological battery, SP women were found to perform worse in a number of cognitive
domains than their SN counterparts [7]. Findings from other cohorts, however, have differed
as to whether gender may impact neuropsychological performance, with most studies either
not demonstrating an effect [8–10] or with the differences being explained by such factors as
level of education or substance use [11]. In recent years it has been demonstrated that neuro-
cognitive impairment in HIV infection correlates with levels of markers of mononuclear
phagocyte activation, in particular, levels of soluble CD14 (sCD14) and soluble CD163
(sCD163) [12–17]. Both markers are proteins that are expressed on the cell surface and
secreted with cellular activation, either from the membrane surface from cytoplasmic vesicles.
In this report, we describe studies in which HIV SP Nigerian women were found to perform
worse on a neuropsychological battery than their male SP counterparts. Such differences
appear to be linked to differences in the pattern of expression of specific biomarkers of HIV
disease activity.
Materials and Methods
Study recruitment and participants
Study participants were consecutively recruited form HIV testing and counseling centers
located at the National Hospital and the University of Abuja Teaching Hospital, both in Abuja,
Nigeria, the nation’s capital city. These hospitals are within a network of sites supported by the
Institute of Human Virology, Nigeria (IHVN) with funds from the U.S. President’s Emergency
Plan for AIDS Relief (PEPFAR) program. All individuals were18 years of age, able to con-
verse in English and were antiretroviral naïve. Information related to demographics, clinical
symptoms and medical, psychiatric and substance use history was obtained through the
administration of standardized questionnaires. Participants were excluded who had active
tuberculosis, syphilis or other CNS infection or evidence of the presence of a clinical problem
that could impair their ability to participate in the testing, including other active CNS or sys-
temic disease, a history of significant head trauma, a history of alcohol abuse, use of other
mind-altering substances, or, if there was a history of substance use, evidence of such use on
urine toxicology screening. There was also no previous diagnosis of a learning disability or
psychiatric disorder or other disorders associated with the presence of focal neurological signs
or deficits. Following enrollment the participants underwent a thorough general medical
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assessment and neuropsychological testing. They also underwent phlebotomy and subsequent
determination of HIV-1 serological status, viral load (limit of detection 400 copies/ml) and
measurement of CD4+ T cell count performed at the Institute of Human Virology, Nigeria-
supported Research Laboratory located in Asokoro, Abuja. Written consent was obtained from
all study participants. Using information obtained from the clinical history and medical exami-
nation, the clinical stage of the participants was determined using the World Health Organiza-
tion clinical classification for established HIV infection (stage 1 = asymptomatic infection;
2 = mild symptoms; 3 = advanced symptoms; 4 = severe symptoms) [18]. All study procedures
were approved by the Institutional Review Boards of the University of Maryland, Baltimore,
the National Hospital in Abuja, Nigeria and University of Abuja Teaching Hospital in Gwag-
walada, Nigeria and by the Nigerian National Health Research Ethics Committee.
Neuropsychological assessment
A detailed standardized neuropsychological battery was administered to all study participants
by an examiner who was blinded to the HIV serological status of the participant. The following
ability domains, followed by the individual tests within the domains in parentheses, were
examined: speed of information processing (WAIS-III Digit Symbol, WAIS-III Symbol Search,
Color Trails Test 1 and Trail Making Test A); attention/working memory (Paced Auditory
Serial Addition Task, and WMS-III Spatial Span); executive functions (Color Trails Test 2 and
Stroop Color and Word Test); learning (Hopkins Verbal Learning Test—Revised (HVLT-R)
total learning and the Brief Visuospatial Memory Test—Revised (BVMT-R) total learning);
memory (HVLT-R delayed recall; BVMT-R delayed recall); verbal fluency (Letter (Word
Sound) Fluency; Category Fluency: Nouns (animals) and Category Fluency: Verbs (actions));
motor speed and dexterity (Grooved Pegboard Test-Dominant Hand, Finger Tapping Test-
Dominant Hand and Timed Gait), and screening for effort (Hiscock Digit Memory Test). Raw
scores from the neuropsychological tests were converted to scaled scores and the scaled scores
were used to generate standardized scores (T-scores) that were adjusted for age, education and
gender. Individual test T-scores were then used to calculate a deficit score, which were averaged
for tests within each cognitive domain to generate a domain deficit score, which were averaged
across all domains to calculate a global deficit score (GDS) [19]. In addition to recruiting only
English speakers, to minimize the potential impact of language or cultural differences on per-
formance on the testing, words were eliminated from verbal tests that were likely to be unfamil-
iar to individuals from the region and, after appropriate pilot testing, were replaced by more
familiar terms. Information regarding the presence and severity of symptoms of depression
were collected using the Beck Depression Inventory-2nd Edition (BDI-II) [20].
Blood sample preparation and storage
Peripheral blood samples were collected in citrate tubes and cells and plasma was separated on
Ficoll gradients as previously described [21]. Aliquots of plasma were stored at -20 degrees
until analyzed.
Enzyme-linked Immunosorbent Assays
Commercially available kits were used to measure plasma soluble CD163 (sCD163; Trillium
Diagnostics) and soluble CD14 (sCD14; R&D Systems) levels, which were measured by
enzyme-linked Immunosorbent assays according the manufacturers’ directions and as previ-
ously described [21]. The limit of detection for the kits was<0.23 ng/ml for sCD163 and 62.5
pg/ml for sCD14.
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Statistical Analysis
Demographic, clinical, immunological and virological data and neuropsychological test T
scores, deficit scores and global deficit scores were compared for SP and SN participants and
by gender using t-tests. Comparisons involving individuals categorized by both HIV serological
status and gender were performed using analysis of variance (ANOVA) with correction for
multiple comparisons using the Tukey multiple comparisons test. Rates of impairment and
select categorical demographic data were examined using the Chi-square test or Fisher’s Exact
Test, as appropriate. Associations between GDS and other variables were examined by calculat-
ing Spearman’s rank correlation coefficients. Percent monocyte values and viral load measure-
ments were log transformed to achieve normality for these data. Statistical significance is
indicated by a p-value<0.05. Statistical analyses were performed using SAS Enterprise Guide
(SAS Institute, Inc.) and GraphPad Prism 6 for Windows (GraphPad Software, Inc.).
Results
Comparison of Demographic and General Clinical Characteristics
Comparison of the demographic and clinical characteristics for the 58 SN and 149 SP partici-
pants showed that SN subjects were younger and had more years of education than SP individ-
uals (Table 1). BDI-II scores were lower for SN than for SP subjects. The percentage of males
and females were similar for the SN and SP participant groups. However, SN men were signifi-
cantly younger than SP men, and SP women were significantly younger than SP men. SN
women and men were more educated than their SP counterparts, and there was no difference
in the level of education for SN women versus SN men and for SP women versus SP men.
Mean depression scores were higher for SP men than for their SN counterparts and higher for
SN women than for SN men. CD4+ T cell counts were lower for SP than for SN participants
and lower for SN and SP men as compared to their female counterparts. Among HIV-infected
individuals, HIV viral load measurements were higher for women than for men, and virus was
more likely to be undetectable among men than among women, but these differences were of
borderline statistical significance. WHO scores could be determined for 70 women and 51 men
and were found to be similar for the individuals in the two groups (p = 0.085; Chi-square test).
Based on the WHO score, 84.29% of the women and 82.35% of the men were determined to
have asymptomatic HIV infection.
Analysis of Individual Neuropsychological Test Scores for SP versus SN
Participants
Analysis of the overall individual neuropsychological test T scores for SN versus SP individu-
als showed a statistically significant difference only on the Letter (Word Sound) Fluency
Test, on which SP individuals performed worse on the test (p = 0.04; Cohen’s d = 0.30). SP
individuals also scored lower on the Stroop Color Word Test, but this difference was of bor-
derline significance (p = 0.06; Cohen’s d = 0.29). Performance on the individual neuropsy-
chological tests were also analyzed by gender (Table 2). For this analysis, differences in test
mean scores for SP and SN women and men were analyzed by ANOVA with subsequent
post-hoc testing for differences between pairs of groups. These studies showed overall differ-
ences in performance on the WAIS-III Digit Symbol, WAIS-III Symbol Search, Stroop Color
and Word Test, Hopkins Verbal Learning Test-Revised total learning, Brief Visuospatial
Memory Test—Revised total learning and with Category Fluency: Verbs (actions). For
women in the study, HIV infection was associated with significantly lower scores on the
WAIS III Digit Symbol test, WAIS-III Symbol Search, Stroop Color and Word tests, the
Cognition, Gender, Monocyte Activation and HIV Infection in Nigeria
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Hopkins Total Learning Test-Revised total learning and the Brief Visuospatial Memory Test
—Revised total learning and Brief Visuospatial Memory Test—Revised delayed recall tests.
SP women also scored lower than SN women on the Letter (Word Sound) Fluency and Cate-
gory Fluency: Nouns (animals) tests, but these differences were of borderline statistical signif-
icance. In contrast to what was noted for women in the study, SP men scored significantly
better on the Brief Visuospatial Memory Test—Revised total learning test and with Category
Table 1. Demographic and Clinical Characteristics for the HIV Seropositive and Seronegative Subjects.
Seronegative (SN) Seropositive (SP) P-value
A. All Patients
Number of participants 58 149
Age (years)1 29.83 (6.41) 34.48 (7.58) <0.0001
Education (years)1 14.00 (2.41) 12.47 (3.27) 0.0003
Median CD4 count (Q1-Q3) 746 (583–898) 345 (210–493) <0.0001
BDI-II 1,2 5.05 (5.54) 7.26 (7.05) 0.019
B. Comparisons by Gender
Number of participants
Women 38 (65.52)2 92 (61.74) 0.613
Men 20 (34.48) 57 (38.26)
Age (years)1
Women 30.66 (7.14) 32.10 (6.43) 0.26
Men 25.25 (4.49) 38.32 (7.77) <0.0001
p-value (Women vs Men) 0.12 < .0001
Education (years)1
Women 14.24 (2.68) 12.70 (2.84) 0.005
Men 13.55 (1.79) 12.11 (3.87) 0.0296
p-value (Women vs Men) 0.31 0.32
BDI-II
Women 6.08 (6.10) 7.60 (6.95) 0.24
Men 3.10 (3.68) 6.70 (7.22) 0.0058
p-value (Women vs Men) 0.025 0.45
Median CD4 count (Q1-Q3)
Women 833.5 (678–977) 363 (242.5–508) <0.0001
Men 631 (469–750.5) 265 (171–419) <0.0001
p-value (Women vs Men) 0.0057 0.018
C. Viral load
Log copies/ml
Women (N = 92) 4.46 (0.76)1
Men (N = 57) 4.04 (1.55)
p-value 0.06
Non-detectable
Women (N = 92) 0/92
Men (N = 57) 3/57
p-value4 0.054
1Mean (Standard Deviation);
2Number (Percent);
3Chi-square test;
4Fisher’s Exact Test. Results that are statistically significant (p<0.05) are in bold letters
doi:10.1371/journal.pone.0147182.t001
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Fluency: Verbs (actions) than SN men. SP men also performed better than SN men on the
finger tapping test, but this difference was of borderline significance. In addition, the effect
size values for several tests demonstrated a better performance for SN versus SP men or
women on the testing despite the fact that such differences were either not significant or of
borderline statistical significance (Table 2).
Table 2. Neuropsychological Performance for SN and SPWomen andMen.
Women Men
ANOVA
P1
SN (N = 38) T
Score (SD)
SP (N = 92) T
Score (SD)
P d2 SN (N = 20) T
Score (SD)
(N = 57) T
Score (SD
P d
Speed of Information
Processing
WAIS-III Digit Symbol 0.02 51.06 (11.25) 46.59 (10.46) 0.03 0.41 49.91 (11.18) 51.66 (10.69) 0.54 -0.16
WAIS-III Symbol
Search
<0.0001 51.07 (9.20) 46.60 (9.52) 0.015 0.48 49.66 (11.60) 54.31 (10.61) 0.10 -0.42
Color Trails Test 1 Trial 0.15 48.66 (10.33) 51.37 (11.96) 0.22 -0.42 49.67 (9.92) 46.74 (10.76) 0.29 0.28
Trail Making Test A 0.60 50.94 (10.19) 49.31 (12.30) 0.47 0.14 48.65 (9.62) 47.60 (11.32) 0.71 0.10
Attention/Working Memory
Paced Auditory Serial
Addition Task
0.73 48.89 (9.95) 49.57 (9.85) 0.72 -0.37 47.91 (13.16) 48.70 (11.76) 0.80 -0.06
WMS-III Spatial Span 0.97 49.98 (10.87) 49.89 (9.44) 0.48 0.01 50.16 (9.05) 50.51 (9.59) 0.89 -0.04
Executive Function
Color Trails Test 2 0.40 49.72 (10.59) 46.28 (10.61) 0.48 0.32 52.58 (10.19) 50.51 (10.07) 0.43 0.20
Stroop Color and Word
Test
0.04 50.91 (10.86) 46.21 (8.72) 0.01 0.48 50.03 (8.12) 49.85 (11.95) 0.95 0.02
Learning
HVLT-R3 total learning 0.009 49.50 (11.06) 45.03 (9.58) 0.02 0.43 48.99 (8.96) 50.15 (9.48) 0.63 -0.13
BVMT-R4 total learning < .0001 50.61 (11.56) 46.76 (10.10) 0.06 0.35 48.86 (10.02) 54.56 (9.23) 0.03 -0.59
Memory
HVLT-R delayed recall 0.1 49.51 (11.43) 46.57 (9.90) 0.14 0.36 48.89 (8.41) 50.49 (9.96) 0.52 -0.17
BVMT-R delayed recall 0.0002 51.30 (9.63) 46.62 (10.56) 0.02 0.46 49.55 (10.62) 54.42 (12.29) 0.12 -0.42
Verbal Fluency
Letter (Word Sound)
Fluency
0.20 50.20 (11.07) 46.57 (8.99) 0.05 0.36 48.02 (8.80) 46.50 (8.37) 0.49 0.18
Category Fluency:
Nouns (animals)
0.29 51.12 (9.60) 47.61 (10.50) 0.07 0.35 45.96 (11.71) 49.88 (9.77) 0.15 -0.33
Category Fluency:
Verbs (actions)
0.0027 49.68 (9.21) 46.91 (11.43) 0.19 0.27 47.23 (8.67) 53.66 (10.97) 0.02 -0.65
Motor Speed and Dexterity
Grooved Pegboard Test 0.79 49.86 (9.43) 50.63 (11.02) 0.71 -0.08 51.21 (9.26) 51.23 (10.13) 0.99 0.00
Finger tapping test 0.83 51.06 (10.73) 52.07 (14.12) 0.69 -0.08 48.41 (7.57) 52.51 (12.34) 0.09 -0.40
Timed gait 0.23 48.47 (9.19) 48.08 (11.10) 0.85 0.04 47.55 (8.19) 44.77 (10.50) 0.29 0.34
Comparisons and results that that either have p<0.1 (which is consistent with at least borderline statistical significance) or have at least a moderate effect
size (0.3) are in bold letters.
1P = p-value.
2d = Cohen’s d.
3Hopkins Verbal Learning Test-Revised.
4Brief Visuospatial Memory Test-Revised.
doi:10.1371/journal.pone.0147182.t002
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Analysis of the Ability Domain and Global Deficit Scores for SP versus
SN Participants
Mean deficit scores for the seven ability domains and the GDS were compared for all SN and
SP individuals (Table 3). SN participants showed better performance with respect to speed of
information processing than SP participants. SN subjects also performed better on tests of
executive function and motor function, but these differences was of borderline statistical signif-
icance. Analysis of global neurocognitive status showed that SN individuals were also overall
less impaired, as demonstrated by a mean GDS measure that was lower for SN subjects than
for SP individuals. The proportion of all SN and SP individuals who scored in a range that
would be considered consistent with NCI were also compared. This analysis showed differ-
ences between all SP and all SN participants with respect to speed of information processing
and executive functioning, with the latter found to be of borderline statistical significance
(Table 3).
Comparison of deficit scores for SP and SN men and women by ANOVA showed differ-
ences with respect to learning and memory functions and with respect to the GDS (Table 4).
As compared to SN women, SP women had significantly lower mean speed of information pro-
cessing and verbal fluency scores and lower scores in executive function and memory that were
of borderline statistical significance. Also, global performance was better for SN women than
for SP women. For men, there was a borderline difference in motor function with SP men
Table 3. Comparison of ability deficit domain scores and frequency of impairment for all study
participants.
Mean Scores SN SP P1, d2
N, Mean (SD) N, Mean (SD)
SIP 58, 0.23 (0.38) 148, 0.36 (0.52) 0.049, 0.29
AWM 56, 0.29 (0.62) 146, 0.22 (0.53) 0.47, -0.12
EF 58, 0.20 (0.46) 149, 0.35 (0.57) 0.075, 0.29
LN 58, 0.29 (0.58) 149 0.35 (0.57) 0.53, 0.10
MEM 58, 0.27 (0.42) 148, 0.33 (0.59) 0.36, 0.12
VF 58, 0.29 (0.56) 148, 0.34 (0.51) 0.52, 0.09
MF 58, 0.22 (0.30) 149, 0.32 (0.42) 0.07, 0.27
GDS 56, 0.25 (0.25) 143, 0.34 (0.33) 0.047, 0.30
% Impaired HIV- HIV+ P
SIP 6/58 39/148 0.01
AWM 7/56 18/146 0.97
EF 6/58 33/149 0.05
LN 8/58 29/149 0.34
MEM 9/58 29/148 0.50
VF 14/58 41/148 0.60
MF 13/58 38/149 0.64
GDS 12/56 39/143 0.40
Comparisons and results that that either have p<0.1 (which is consistent with at least borderline statistical
significance) or have at least a moderate effect size (>0.3) are in bold letters.
1P = p-value.
2d = Cohen’s d.
SIP = speed of information processing; AWM = attention/working memory; EF = effector functions;
LN = learning; MEM = memory; VF = verbal fluency; MF = motor function; GDS = global deficit score.
doi:10.1371/journal.pone.0147182.t003
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performing worse than SN men. Analysis of the frequency of impairment on the testing
showed overall differences for speed if information processing, learning and memory for SN
and SP men and women (Table 4). Also, SP women were more frequently impaired than SN
women on tests of speed of information processing.
Analysis of Neuropsychological Test Performance for SP and SN
Women and Men by Two-Way ANOVA
Individual neuropsychological test and ability domain deficit scores, GDS and individual
neuropsychological test T scores were also compared by gender and serostatus using 2-way
ANOVA (Table 5). This analysis showed no differences for SN women and SN men, SN
women and SP men or for SP women and SN men (data not shown). Differences were
observed, however, on the following tests with scores for SP women that were lower than for
SP men: the WAIS-III Symbol Search, the Hopkins Total Learning test, the Brief Visuospatial
Memory Test—Revised, the Brief Visuospatial Memory Test—Revised—delayed recall and the
Category Fluency: Verbs (actions) test. In addition, SP women had significantly higher learning
and memory deficit scores than SP men and, therefore, were more impaired in these domains.
There was, however, no difference in the frequency of impairment in the ability domains or
with respect to mean GDS (data not shown).
Table 4. Comparison of ability domain scores and frequency of impairment for women versusmen.
Women Men
Mean Scores ANOVA SN SP P, d3 SN SP P, d
(F1, P2) N, Mean (SD) N, Mean (SD) N, Mean (SD) N, Mean (SD)
SIP 1.64, 0.18 38, 0.18 (0.30) 92, 0.39 (0.56) 0.008, 0.47 20, 0.31 (0.51) 56, 0.30 (0.47) 0.10, -0.20
AWM 0.41, 0.74 36, 0.29 (0.59) 90, 0.19 (0.45) 0.38, -0.19 20, 0.28 (0.68) 56, 0.27 (0.63) 0.97, -0.20
EF 1.23, 0.30 38, 0.20 (0.46) 92, 0.38 (0.61) 0.10, 0.33 20, 0.20 (0.47) 57, 0.30 (0.52) 0.46, 0.20
LN 3.58, 0.015 38, 0.32 (0.62) 92 0.46 (0.63) 0.23, 0.21 20, 0.25 (0.50) 57, 0.17 (0.38) 0.44, -0.18
MEM 4.04, 0.008 38, 0.28 (0.45) 91, 0.45 (0.67) 0.09,0.30 20, 0.25 (0.38) 57, 0.15 (0.38) 0.31, -0.26
VF 1.52, 0.21 38, 0.22 (0.40) 91, 0.40 (0.54) 0.04, 0.38 20, 0.43 (0.77) 57, 0.26 (0.48) 0.36, -0.26
MF 1.04, 0.38 38, 0.25 (0.32) 92, 0.31 (0.42) 0.38, 0.16 20, 0.18 (0.28) 57, 0.33 (0.46) 0.09, 0.39
GDS 2.71, 0.046 36, 0.23 (0.23) 88, 0.38 (0.35) 0.0058, 0.51 20, 0.30 (0.31) 55, 0.27 (0.30) 0.87, -0.10
% Impaired P HIV- HIV+ P HIV- HIV+ P
SIP 0.02 2/38 26/92 0.004 4/20 13/56 1.0
AWM 0.64 4/36 9/90 1.0 3/20 9/56 1.0
EF 0.30 4/38 22/92 0.1 2/20 11/57 0.49
LN <0.01 6/38 25/92 0.17 2/20 4/57 0.65
MEM <0.04 6/38 24/91 0.19 3/20 5/57 0.42
VF 0.173 8/38 31/91 0.14 6/20 10/57 0.24
MF 0.96 9/38 22/92 0.98 4/20 16/57 0.57
GDS 0.16 7/36 29/88 0.13 5/20 10/55 0.51
1F = F-statistic.
2P = p-value.
3d = Cohen’s d.
Comparisons and results that either have p<0.1 (which is consistent with at least borderline statistical significance) or have at least a moderate effect size
(>0.3) are in bold letters. SIP = Speed of Information Processing; AWM = attention/working memory; EF = effector functions; LN = learning;
MEM = memory; VF = verbal fluency; MF = motor function; GDS = global deficit score.
doi:10.1371/journal.pone.0147182.t004
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Comparison of Monocyte, sCD14 and sCD163 Measures for HIV SP
and SN Individuals
Numbers of circulating monocytes and plasma levels of sCD14 and sCD16 were compared for
all HIV SP and SN participants and for SP and SN women and men in the cohort (Fig 1).
These studies showed that absolute monocyte numbers were overall higher for SP than for SN
individuals. Also, circulating monocyte numbers for SP women and SP men were higher than
those for their SN counterparts and numbers for SP participants overall and for SP men were
also higher than those for SN individuals overall and higher than for SN women.
For sCD14, levels were also overall higher for SP than for SN individuals and higher for SP
women than for SN women and for SP men then for SN men. Other comparisons showed
that levels for nearly all SP groups were higher than those for any of the SN groups. Also, SP
women had sCD14 levels that were higher than SP men, but this difference was a borderline
statistical significance. For sCD163, measurements for all SP individuals were higher than for
those in any of the SN groups.
Table 5. Differences in Neuropsychological Test Performance and in Ability and Global Deficit Scores for SPWomen versus SP Men.
Test or Domain Score Comparison P1, d2 95% Confidence Interval for the Difference in Scores
Neuropsychological Test T Score
SP Women versus SP Men
WAIS-III Symbol Search 0.0001, -0.77 -9.93 to -5.14
Hopkins Total Learning 0.03, -0.53 -9.73 to -0.29
Brief Visuospatial Memory Test—Revised <0.0001, -0.79 -13.03 to -2.98
Brief Visuospatial Memory Test—Revised—Delayed Recall 0.0003, -0.70 -13.33 to -2.72
Category Fluency: Verbs (actions) 0.004, -0.59 -11.79 to -1.41
Ability Domain Deficit Score
Learning 0.018, 0.80 0.03 to 0.57
Memory 0.01, 0.57 0.05 to 0.57
1P = p-value.
2d = Cohen’s d.
doi:10.1371/journal.pone.0147182.t005
Fig 1. Comparison of monocyte, sCD14 and sCD163measurements. A comparison was performed of (a)
log10(%monocyte), (b) sCD14 and (c) sCD163 measurements for all SN and SP subjects and for SN and SP
women and men. In nearly all cases, significant differences between SN and SP individuals overall and
between the female and male gender groups. Similar levels of these measures were observed for the various
SP groups (see the text for additional details).
doi:10.1371/journal.pone.0147182.g001
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Correlations between GDS and Monocyte, sCD14 and sCD163
Measures
Correlations between GDS, monocyte numbers, sCD14, sCD163 and numbers of CD4+ T cells
were examined for all SN and SP participants and for the gender and HIV serostatus subgroups
(Table 6A). No correlation was observed between any of these measures among SN subjects
overall or for SN women. GDS correlated with sCD14 and, at a borderline level of significance,
with sCD163 levels among all SP participants, with only sCD14 levels among SP women and,
at a borderline level of significance, with sCD163 among SN men. Monocyte numbers corre-
lated inversely with CD4+ T cell counts among all SP groups as well as among SN men.
For SP individuals, correlations with HIV viral load were also examined (Table 6B). These
studies showed, for all groups, significant inverse correlations for CD4+ T cell counts and viral
load measurements. For GDS, a significant correlation with viral load was observed for the
entire group of SP individuals and borderline statistically significant correlations for SP women
and SP men. Among the entire group of SP individuals and for SP women, significant correla-
tions were observed between viral load and percent monocyte, sCD14 and sCD163 measure-
ments; however, no significant correlations were observed between viral load and these
measures for SP men.
Discussion
In this study we report results that confirm our previous findings demonstrating the occur-
rence of neurocognitive impairment among a cohort of individuals in Nigeria with HIV infec-
tion [6]. We also demonstrate the presence of increased monocyte numbers and, as reported
for other cohorts [12–14,22,23], elevated levels of monocyte activation among infected individ-
uals. A surprising result was the finding that individuals who demonstrated impairment on
the individual neuropsychological tests and within the specific ability domains were primarily
women. Furthermore, in a multivariate analysis we showed that the differences that were
observed were specifically between SP women and SP men. Results similar to these findings, as
well as the observation that SP men also performed better than SN men on the testing, were
obtained by Hested et al in studies involving a smaller cohort in Zambia [7]. In two other previ-
ously reported studies, HIV-infected women were also more likely than men to present with
neurologic symptoms and evidence of neurologic disability [24] and to progress more rapidly
to AIDS despite having similar viral plasma load measurements [25]. The latter study, however,
involved individuals who were illicit drug users, and such individuals were excluded from our
Nigeria cohort. Also, the finding that gender can impact the rate of progression of neurological
disease or time to the development of AIDS has not been replicated in other studies [26,27].
The reasons for our observations involving SP women in our study are unclear, and the
findings are particularly striking given the fact that the SP women were younger and had higher
CD4+ T cell counts than their male counterparts, factors that are generally associated with a
better performance on the neuropsychological testing [28,29]. Also, BDI-II scores were similar
for SP women, SN women and SP men, and in the subclinical range. Therefore, the reason for
the poor overall performance by SP women on the testing cannot be explained by the presence
of symptoms of depression. Previous studies of gender effects on performance on the specific
neuropsychological tests that were included in the study battery show that women may per-
form better on the Stroop test with respect to color naming and word reading and on the
Grooved Pegboard test [30]. Men, on the other hand, tend to perform better on the Finger-tap-
ping test [30]. This notwithstanding, tests scores in our study were adjusted for demographic
effects based on the performances of the SN group. Among the other factors that could under-
lie the presence of impairment among SP women include hormonal effects, which may
Cognition, Gender, Monocyte Activation and HIV Infection in Nigeria
PLOS ONE | DOI:10.1371/journal.pone.0147182 February 1, 2016 10 / 16
Table 6. Correlations (p-values) between Clinical Laboratory Parameters of HIV Infection and Measures of Monocyte Activation by Subject HIV
Serostatus and Gender.
A. Correlations for All SP and SN Participants
GDS Monocytes sCD14 sCD163 CD4 Count
All SN
GDS 0.048 (0.75) 0.003 (0.98) 0.216 (0.11) 0.184 (0.17)
Monocytes 0.048 (0.75) 0.206 (0.16) 0.085 (0.56) -0.165 (0.26)
sCD14 0.003 (0.98) 0.206 (0.16) 0.0116 (0.91) -0.017 (0.90)
sCD163 0.216 (0.11) 0.085 (0.56) 0.016 (0.91) -0.014 (0.92)
CD4 Count 0.184 (0.17) -0.165 (0.26) -0.017 (0.90) -0.014 (0.92)
All SP
GDS -0.062 (0.48) 0.212 (0.011) 0.153 (0.069) -0.038 (0.66)
Monocytes -0.062 (0.48) 1.74 E-6 (1.0) 0.116 (0.17) -0.329 (<0.0001)
sCD14 0.212 (0.011) 1.74 E-6 (1.0) 0.089 (0.28) -0.136 (1.0)
sCD163 0.153 (0.069) 0.116 (0.17) 0.089 (0.28) -0.125 (0.13)
CD4 Count -0.038 (0.67) -0.329 (<0.0001) -0.136 (1.0) -0.125 (0.13)
SN Women
GDS 0.150 (0.43) -0.006 (0.97) 0.007 (0.97) 0.277 (0.10)
Monocytes 0.150 (0.43) 0.113 (0.54) 0.199 (0.28) -0.070 (0.71)
sCD14 -0.006 (0.97) 0.113 (0.54) 0.079 (0.64) 0.115 (0.49)
sCD163 0.007 (0.97) 0.199 (0.28) 0.079 (0.64) 0.027 (0.87)
CD4 Count 0.277 (0.10) -0.070 (0.71) 0.115 (0.49) 0.027 (0.87)
SP Women
GDS 0.019 (0.87) 0.366 (<0.0001) 0.176 (0.10) -0.153 (0.15)
Monocytes 0.019 (0.87) -0.063 (0.56) 0.155 (0.15) -0.330 (0.002)
sCD14 0.366 (<0.0001) -0.063 (0.56) 0.069 (0.51) -0.10 (0.35)
sCD163 0.176 (0.10) 0.155 (0.15) 0.069 (0.51) -0.203 (0.05)
CD4 Count -0.153 (0.15) -0.330 (0.002) -0.100 (0.35) -0.203 (0.05)
SN Men
GDS -0.357 (0.46) 0.012 (0.96) 0.447 (0.063) 0.142 (0.58)
Monocytes -0.357 (0.19) 0.318 (0.25) -0.258 (0.35) -0.542 (0.037)
sCD14 0.012 (0.96) 0.318 (0.31) -0.055 (0.83) -0.265 (0.29)
sCD163 0.447 (0.063) -0.258 (0.37) -0.055 (0.83) -0.159 (0.53)
CD4 Count 0.142 (0.58) -0.542 (0.037) -0.265 (0.28) -0.159 (0.53)
SP Men
GDS -0.143 (0.32) -0.057 (0.68) 0.083(0.54) 0.078 (0.56)
Monocytes -0.143 (0.32) 0.094 (0.51) 0.132 (0.35) -0.277 (0.047)
sCD14 -0.057 (0.68) 0.094 (0.51) 0.145 (0.27) -0.176 (0.18)
sCD163 0.083 (0.54) 0.132 (0.35) 0.145 (0.27) -0.077 (0.56)
CD4 Count 0.078 (0.56) -0.277 (0.047) -0.176 (0.18) -0.077 (0.56)
B. Correlations (p-values) with Viral Load
GDS Monocytes sCD14 sCD163 CD4 Count
All SP 0.222 (0.008) 0.219 (0.01) 0.174 (0.034) 0.220 (0.007) -0.388 (<0.0001)
SP Women 0.191 (0.075) 0.330 (0.002) 0.266 (0.01) 0.264 (0.01) -0.554 (<0.0001)
SP Men 0.241 (0.077) 0.176 (0.22) 0.138 (0.31) 0.176 (0.19) -0.381 (0.0035)
Results that are of at least borderline statistical significance (p<0.1) are in bold letters.
doi:10.1371/journal.pone.0147182.t006
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modulate immune responses to either increase or decrease protective immunity in HIV infec-
tion. In this regard, it has been observed that estrogens and progestin may increase immune
reactivity to antigens, the expression of immune mediators and circulating CD4+ T cell num-
bers, with such effects changing at the different phases of the menstrual cycle [31]. Other possi-
bilities are that differences may exist in the availability of healthcare to the women who we
enrolled into the study or that socio-cultural, economic (lower income), educational or other
factors may exist for the women that could predispose them to developing neurocognitive
impairment or not performing as well on the tests. Such factors could also explain why on sev-
eral tests SP men performed better than SN men.
HIV enters the central nervous system early in infection, where it is likely transported by
infected monocytes [32]. Once in the nervous system, toxicity is induced by direct effects from
HIV products and inflammatory mediators that are secreted by activated phagocytes in the
brain [33]. Among the SP individuals and SN men in our cohort, peripheral blood monocyte
numbers and markers of monocyte activation were found to be elevated and showed an inverse
correlation with CD4+ T cell counts. This has been previously described and is likely a reflec-
tion of the relative lymphopenia that occurs as a result of HIV infection [34]. The reason for
this observation among SN men is unclear. Other factors that can impact circulating monocyte
numbers in men include increased serum cholesterol levels, which can decrease numbers of
monocytes and cigarette smoking [35,36]. In both men and women monocyte numbers can be
increased by exercise [37]. None of these factors were examined as a part of this study, how-
ever. We also found that levels of the measured monocyte activation markers correlated with
severity of global impairment. This is consistent with several studies that have demonstrated
that the presence and severity of neurocognitive impairment among infected individuals corre-
late with levels of sCD14 and sCD163 in plasma [12,13]. In the studies that we report here, not
only did we show that sCD14 and sCD163 levels are increased among HIV SP individuals in
the cohort, but we also provide the first demonstration of increased numbers of blood mono-
cytes among infected individuals in association with an increase in the levels of these activation
markers. In addition, sCD14 levels were slightly higher for SP women than for SP men, which
is consistent with the finding that SP women performed worse on the neuropsychological test-
ing than SP men. CD14, the endotoxin receptor, is produced by monocytes and macrophages
and, in binding lipopolysaccharide, uses Toll receptor 4 (TLR4) as a co-receptor. Soluble CD14
is secreted by the cells following activation and increased levels of sCD14 occur in association
with elevated levels of lipopolysaccharide and, in HIV infection, with microbial translocation
[38] and the presence of neurocognitive impairment [12–14,22,23].
CD163 is a hemoglobin scavenger receptor that is also produced by monocytes and macro-
phages [39–43]. Like sCD14, levels of sCD163 are increased by LPS, and this effect has been
demonstrated to occur in vitro and in vivo [41,42,44]. In vitro sCD163 can inhibit the prolifera-
tion of T cells in culture [45], and, therefore, may have immunosuppressive effects in vivo
that could promote earlier development of more advanced disease. In normal and in HIV-
1-infected brain, CD163 is expressed by perivascular macrophages that are likely derived from
CD14+CD16+CD163+ monocytes circulating in peripheral blood [46]. In studies performed
by Fitch et al it was demonstrated plasma levels of sCD163 are higher in women than in men
[47]. However, the patients in this study were older than our study participants, were on treat-
ment with antiretroviral drugs, and their neurocognitive status was not assessed [47]. Blood
CD16+ monocytes may be also more likely to be infected with HIV-1 [48], and in a study per-
formed during the pre-ART era, it was found that numbers of CD14+CD16+ monocyte are ele-
vated in individuals with HIV-associated dementia [17], which is associated with decreased
survival [49]. Elevated sCD14 levels have been linked with an increased mortality [16,50], and,
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the same is likely for sCD163, which is associated with an increased risk of development of
HIV-associated dementia [49,51],
HIV viral load measures were associated with lower CD4+ T cell counts among all partici-
pant groups. Viral load measures were also slightly higher for women than for men, and
women were less likely to have non-detectable virus than men. Viral load levels correlated with
global impairment for the cohort overall but showed a borderline correlation with GDS for
both women and men, likely as a result of the smaller numbers of individuals in the subgroups.
For the activation markers, correlations for sCD14 and sCD163 with viral load were noted
for only women in the study. These findings further highlight the likelihood that mechanisms
that underlie the development of HIV-related neurocognitive impairment differ for women
and men.
Conclusion
In conclusion, SP women in our Nigerian cohort performed worse than SP men on a number
of neuropsychological tests, representing several cognitive domains. These findings among
women were associated with a borderline higher HIV viral burden; however, the viral load
measures correlated with levels of the measured immune markers. Global impairment in
women was associated with elevated levels of one of these markers, sCD14. Such gender-spe-
cific findings have not been previously demonstrated in any HIV-infected cohort. Our ability
to observe such differences may be due to the fact that most study participants had clinically
asymptomatic HIV infection. With that passage of time and the development of HIV-related
symptoms and initiation of antiretroviral therapy, the differences will likely become more diffi-
cult to identify. There are several other important limitations to this study. These include the
relatively small overall sample size and the fact that the group sizes were unbalanced for SN
versus SP participants in general and for women versus men. Such limitations could have influ-
enced the outcome of specific analyses. For example, the relatively small number of SN may
have resulted in decreased precision in the calculation and application of demographic adjust-
ments. This is likely reflected in the borderline level of statistical significance found for some
analyses, particularly comparisons involving data from men, who comprised just slightly over
one third of all individuals in the cohort. Therefore, the results that we report here will need to
be confirmed in future analyses of data from a larger number of study participants. It is also
possible that the findings may have been influenced by an inadvertent selection bias that
resulted from the fact that participants were recruited from counseling and testing centers
located within the two hospitals in Abuja. In this context, it is possible that men may avoid
hospital settings as places to seek HIV testing and counseling. It is also possible that, due to
sociocultural issues, the neuropsychological test battery was limited in its ability to detect
abnormalities equally in men and women. However, for areas of the world where resources are
limited, information such as that which is described in this report could provide an opportu-
nity for early intervention and to otherwise provide care to infected individuals at a time when
the disease burden may be lower. Doing so may offer the potential to improve clinical out-
comes for individuals following the initiation of treatment and to potentially decrease the over-
all expense of care.
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